The Dispersome® technology allows formulation of poorly soluble small molecule drugs into stable amorphous formulations with a high drug load.
Our Dispersome® platform is based around a class of novel excipients to formulate poorly soluble small molecule drugs into stable amorphous formulations with a high drug load.
By increasing solubility and dissolution rate the Dispersome® platform aims at improving bioavailability, therapeutic outcomes and convenience for patients.
Dispersome® formulations are compatible with standard solid oral dosage form manufacturing processes and facilities.
Zerion is a pharmaceutical development company improving the formulation of poorly soluble drugs (oral solid dosage forms) that are currently not reaching their therapeutic potential. Through the use of our proprietary formulation platform, Dispersome®, we aim to develop new treatment options for patients across all therapeutic areas.
Learn moreUp to 90 % of all new drug molecules are poorly soluble, which can be a problem as the drug must dissolve in order to be absorbed and reach its pharmacological target.
AUGUST 29, 2022 (COPENHAGEN, Denmark). The Danish pharmaceutical company Zerion Pharma A/S (ZERION) and the Spanish pharmaceutical group Insud Pharma, SL today are announcing their collaboration to develop
AUGUST 23, 2022 (COPENHAGEN, Denmark). Zerion Pharma A/S (ZERION) and Hovione today announced an extension of their collaboration on ZERION’s Dispersome® technology into the nutraceutical/dietary supplements field.
February 23, 2022 (COPENHAGEN, Denmark). Zerion Pharma A/S (“ZERION”) announces today that it has executed a long-term agreement with Arla Foods Ingredients covering the supply of its Lacprodan® BLG-100 for use as